Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AptarGroupATR +0.65%78 Debt-to-Equity is 0.54 as of Mar. 2026, which is 17% below its 10-year median of 0.65. GuruFocus rates ATR with a GF Score™ of 78/100 and a GF Value™ of $157.49 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 705 Medical Devices & Instruments companies, AptarGroup ranks worse than 71.35% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for AptarGroup's Debt-to-Equity or its related term are showing as below:
ATR'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.42 Med: 0.65 Max: 1.15
Current: 0.54
During the past 13 years, the highest Debt-to-Equity Ratio of AptarGroup was 1.15. The lowest was 0.42. And the median was 0.65.
ATR's Debt-to-Equity is ranked worse than 71.35% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ATR: 0.54
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
AptarGroup Debt-to-Equity Related Terms
AptarGroup Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for AptarGroup's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, AptarGroup's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AptarGroup Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, AptarGroup's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where AptarGroup's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AptarGroup (ATR) has a Debt-to-Equity of 0.54 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AptarGroup and its competitors. This is 17% below median its historical median of 0.65. Over the past decade, AptarGroup's Debt-to-Equity has ranged from 0.42 to 1.15. According to the industry distribution chart, AptarGroup ranks #503 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 71.3%.
Is AptarGroup's Debt-to-Equity too high?
AptarGroup's current Debt-to-Equity of 0.54 is 17% below median its 10-year median of 0.65. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 1.15. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. AptarGroup's value of 0.54 is 134.8% above this industry median. Based on the distribution chart, AptarGroup ranks #503 out of 705 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, AptarGroup has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AptarGroup's Debt-to-Equity compare to RGEN and AVTR?
According to the Medical Devices & Instruments industry distribution chart, AptarGroup ranks #503 out of 705 companies for Debt-to-Equity. This places AptarGroup in the lower half of its industry. The industry median Debt-to-Equity is 0.23. AptarGroup's value of 0.54 is 134.8% above this benchmark. Historically, AptarGroup's own Debt-to-Equity has ranged from 0.42 to 1.15 over the past decade. While the company's 10-year median is 0.65 vs. the industry median of 0.23, AptarGroup has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AptarGroup's current Debt-to-Equity of 0.54 is 134.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on AptarGroup and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AptarGroup's current Debt-to-Equity is 0.54, which is 17% below median its own 10-year median of 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AptarGroup stock overvalued right now?
Based on GuruFocus' analysis, AptarGroup (ATR) is currently considered Modestly Undervalued. The stock's GF Value™ is $157.49, compared to a current price of $129.11 — trading 18% below its estimated fair value. The current Debt-to-Equity is 0.54, which is 17% below median its 10-year median of 0.65 and 134.8% above the Medical Devices & Instruments industry median of 0.23. AptarGroup's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For AptarGroup (ATR), the current Debt-to-Equity is 0.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AptarGroup (ATR) Overvalued in 2026?
Based on GuruFocus' analysis, AptarGroup stock appears to be undervalued.
The current stock price of $129.11 is trading 18% below its estimated GF Value™ of $157.49.
GuruFocus considers AptarGroup to be Modestly Undervalued.
Key valuation signals for ATR:
Debt-to-Equity: 0.54 (17% below median its 10-year median of 0.65)
GF Value™: $157.49 vs. price of $129.11 (18% below fair value)
Industry Position: 134.8% above the Medical Devices & Instruments median (#503 of 705)
No single metric tells the full story. See the ATR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Headquartered in Crystal Lake, Illinois, AptarGroup is a leading global supplier of dispensing systems such as aerosol valves, pumps, closures, and elastomer packaging components to the consumer goods and pharmaceutical markets. Its sales are primarily from Europe (49% of sales) and the United States (28%), with China contributing 5% and other countries contributing 17%. It operates three business segments, Pharma, Beauty, and Closures. Pharma generates over two thirds of group profits.
78GF Score
Get the complete analysis for ATR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATR has been successfully added to your 
